The Relative Strength (RS) Rating for HealthEquity climbed into a higher percentile Thursday, as it got a lift from 69 to 74.
Can You Really Time The Stock Market?
This proprietary rating tracks technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the top-performing stocks often have an RS Rating of at least 80 as they launch their largest runs. See if HealthEquity can continue to show renewed price strength and hit that benchmark.
While it's not currently an ideal time to buy shares, see if the stock is able to establish and enter a buying range in heavy trade.
Earnings growth picked up last quarter from 10% to 21%. But sales fell from 19% to 15%.
HealthEquity holds the No. 1 rank among its peers in the Commercial Services-Outsourcing industry group. HealthEquity and WNS (Holdings) are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
